Skip to main content

Advertisement

Table 1 A selection of published surveys concerning possible clinical benefits (transmission or progression) of the CCR5-delta32 heterozygous genotype

From: Coregulation of HIV-1 dependency factors in individuals heterozygous to the CCR5-delta32 deletion

N= Study population Benefit tested Significance Reference
1427 HIV + vs. sero-negative control group Transmission P = 0.012 [8]
30 ESN Transmission P = 0.04 [9]
54 ESN Transmission P = 0.05* [10]
2605 Woman Transmission OR: 0.63 (95% CI 0.44-0.90) [11]
2996 High risk groups Transmission Risk = 0.30 (95% CI: 0.08-0.97) [12]
1252 MSM Transmission NS [13]
1200 HIV + vs control Transmission, progression to AIDS Both significant [14]
108 IDU Progression to AIDS NS [15]
127 Children Progression to AIDS Significant (p = 0.008) Effect is abrogated in case of a SDF1-3′A genotype [16]
1955 Hemophilia patients Progression to AIDS Significant [17]
512 Mother-child Transmission, progression to AIDS NS, significant [18]
  1. These controversial data suggest that there might be additional factors beside the CCR5-delta32 genotype like SDF 1-3′ which contribute to the clinical outcome of transmission and infection. (ESN = exposed seronegative, MSM = men having sex with men, IDU = injecting drug users, CI = confidence interval, OR = odds ratio, NS = not significant) *only significant in heterosexuals.